BrightSpring Health Services, Inc. Common Stock
BTSG
$70.50
-0.27%
BrightSpring Health Services is a home and community-based healthcare platform delivering complementary pharmacy and provider services to complex patients across Medicare, Medicaid, and commercial populations. As a leading provider in the healthcare services space, it distinguishes itself through an integrated model combining clinical services with pharmacy solutions, generating the majority of its revenue from the Pharmacy Solutions segment. The current investor narrative centers on the company's rapid growth trajectory, margin expansion, and strategic portfolio optimization following the sale of its ResCare Community Living business to Sevita in March 2026. Attention is also focused on its ability to sustain momentum in serving high-acuity patients while navigating regulatory dynamics across government and commercial payers.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$70.50
Related headlines
Investment Opinion: Should I buy BTSG Today?
Rating: Buy. Thesis: BrightSpring's accelerating revenue growth (25.6% YoY), rapid margin expansion, and strong free cash flow generation make it a compelling growth story, supported by unanimous analyst bullishness (Strong Buy consensus, average target $75.22).
Supporting Evidence: The trailing P/E of 39.8x is justified by revenue growth of 25.6% YoY (vs. industry ~10%), net margin improvement from 0.9% to 4.1% over four quarters, and TTM free cash flow of $412.1M. The forward P/E of 33.1x implies continued earnings growth. The P/S ratio of 0.59x is reasonable relative to revenue scale. Analyst average target of $75.22 implies 6.4% upside, with high target of $90.00 offering 27.3% upside.
Risks & Conditions: Key risks include growth deceleration, margin compression, and elevated debt (D/E 1.44). This Buy would downgrade to Hold if revenue growth falls below 15% or net margin drops below 3%. Upgrade to Strong Buy if net margin exceeds 5% and revenue growth accelerates above 30%. Overall, the stock appears fairly valued relative to its growth trajectory but carries execution risk.
Sign up to view all
BTSG 12-Month Price Forecast
The AI assessment is bullish with medium confidence. BrightSpring's accelerating revenue growth and rapid margin expansion are strong positive signals, and the unanimous analyst support reinforces the bullish case. However, the elevated valuation (P/E 39.8x) and high beta (1.795) introduce risk. The base case of 50% probability reflects a likely moderation in growth, but the bull case (30%) is supported by the current trajectory. The stance would be upgraded to high confidence if net margins exceed 5% and revenue growth remains above 20% for two consecutive quarters. Conversely, a downgrade to neutral would occur if growth decelerates below 15% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $76.00 and implied upside of +7.8% versus the current price.
Average Target
$76.00
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$49 - $90
Analyst target range
BrightSpring is covered by 18 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.16 on a 1-5 scale, where 1 is Strong Buy). The average price target is $75.22, implying approximately 6.4% upside from the current price of $70.69. The distribution shows 0 holds and 0 sells, reflecting unanimous bullish sentiment among analysts. Recent ratings from major firms (Morgan Stanley, KeyBanc, Wells Fargo, UBS, BofA, BTIG, TD Cowen, Goldman Sachs) have all been Overweight or Buy, with no downgrades in the past three months, indicating strong institutional conviction. The target range spans from a low of $49.00 to a high of $90.00, representing a spread of $41.00 (55% of the average target). The high target of $90.00 implies 27.3% upside and likely assumes continued revenue acceleration, margin expansion to above 5% net margins, and multiple expansion as the company demonstrates sustainable profitability. The low target of $49.00, which is 30.6% below the current price, may reflect a scenario of decelerating growth, regulatory headwinds, or margin compression. The wide spread indicates elevated uncertainty, but the strong buy consensus and recent upgrades suggest analysts lean toward the optimistic scenario.
Bulls vs Bears: BTSG Investment Factors
BrightSpring presents a compelling growth story with accelerating revenue (25.6% YoY), rapidly expanding margins (net margin from 0.9% to 4.1%), and strong free cash flow generation ($101.4M in Q1). The bull case is supported by unanimous analyst bullishness and strategic portfolio optimization. However, the stock trades at a premium valuation (P/E 39.8x vs. industry 22x) and carries high volatility (beta 1.795). The single most important tension is whether the company can sustain its growth acceleration and margin expansion to justify its premium valuation. If growth decelerates or margins stall, the stock could face significant multiple compression. Currently, the bull case has stronger evidence given the accelerating fundamentals and strong analyst support, but investors must monitor growth sustainability and debt levels.
Bullish
- Accelerating Revenue Growth: Revenue grew 25.6% YoY in Q1 2026 to $3.61B, accelerating from 22.1% in Q4 2025 and 14.5% in Q3 2025, driven by the Pharmacy Solutions segment. This outpaces the healthcare services industry average of ~10%.
- Rapid Margin Expansion: Net margin improved from 0.9% in Q2 2025 to 4.1% in Q1 2026, with net income surging to $148.8M from $28.2M. Gross margin expanded to 13.3% from 11.6% in Q4 2025, reflecting operating leverage.
- Strong Free Cash Flow Generation: Free cash flow was $101.4M in Q1 2026, contributing to TTM FCF of $412.1M. This provides financial flexibility for debt reduction or reinvestment, supporting the debt-to-equity ratio of 1.44.
- Unanimous Analyst Bullishness: All 18 analysts rate the stock a Strong Buy (mean 1.16), with an average target of $75.22 implying 6.4% upside. No holds or sells, and recent upgrades from major firms like Morgan Stanley and Goldman Sachs.
Bearish
- Elevated Valuation Premium: Trailing P/E of 39.8x is 81% above the healthcare services industry average of ~22x. While growth justifies some premium, any deceleration could lead to multiple compression.
- High Beta and Volatility Risk: Beta of 1.795 means the stock is 80% more volatile than the S&P 500. A market downturn could amplify losses, and the stock's 52-week low of $19.01 represents a 73% downside from current levels.
- Wide Analyst Target Range: Analyst targets range from $49.00 (30.6% downside) to $90.00 (27.3% upside), indicating significant uncertainty. The low target implies a scenario of growth deceleration or margin compression.
- Elevated Debt Levels: Debt-to-equity ratio of 1.44 is high, and interest expense of $38.6M in Q1 2026 consumes a portion of operating income ($121.4M). Rising interest rates could pressure earnings.
BTSG Technical Analysis
BrightSpring is in a powerful sustained uptrend, with the stock surging 251.7% over the past year, dramatically outperforming the S&P 500's 18.4% gain. The current price of $70.69 sits at 97.9% of its 52-week range ($19.01–$72.22), indicating the stock is near its all-time highs and reflecting strong bullish momentum. This positioning near the top of the range suggests the market is pricing in continued positive fundamentals, though it also raises the risk of short-term overextension. Short-term momentum remains robust, with the stock gaining 9.7% over the past month and 49.5% over the past three months, both far exceeding the S&P 500's respective returns of 0.3% and 4.7%. The 1-month change of 9.7% is consistent with the longer-term uptrend, showing no signs of divergence or deceleration. The relative strength versus the S&P 500 over 1-month (9.4%) and 3-month (44.9%) confirms that the stock is experiencing strong, broad-based buying pressure. The 52-week high of $72.22 serves as immediate resistance; a breakout above this level would signal a continuation of the uptrend and likely attract further momentum buying. Support lies at the 52-week low of $19.01, though more relevant near-term support is around the $60 level, which acted as resistance in May 2026 and now flips to support. With a beta of 1.795, the stock is approximately 80% more volatile than the S&P 500, meaning it amplifies market moves—a factor that warrants careful position sizing and risk management.
Beta
1.79
1.79x market volatility
Max Drawdown
-17.9%
Largest decline past year
52-Week Range
$19-$73
Price range past year
Annual Return
+253.5%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | +6.4% | -0.6% |
| 3m | +52.9% | +5.4% |
| 6m | +79.7% | +8.3% |
| 1y | +253.5% | +18.3% |
| ytd | +83.6% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
Revenue growth is accelerating impressively, with Q1 2026 revenue of $3.61 billion representing a 25.6% year-over-year increase, up from 22.1% YoY growth in Q4 2025 ($3.55 billion) and 14.5% in Q3 2025 ($3.33 billion). The sequential acceleration is driven by the Pharmacy Solutions segment, which benefits from increased patient volumes and favorable payer mix. Commercial insurance revenue of $1.01 billion and Medicaid revenue of $406 million highlight the diversified payer base supporting growth. Profitability is improving rapidly, with net income rising to $148.8 million in Q1 2026 (net margin 4.1%) from $77.1 million in Q4 2025 (net margin 2.2%) and just $28.2 million in Q2 2025 (net margin 0.9%). Gross margin expanded to 13.3% in Q1 2026 from 11.6% in Q4 2025, reflecting operating leverage and cost management. The company's balance sheet shows improving financial health, with free cash flow of $101.4 million in Q1 2026, up from $193.9 million in Q4 2025 (which included working capital benefits). The debt-to-equity ratio of 1.44 is elevated but manageable given the cash generation, and the current ratio of 1.57 indicates adequate liquidity. ROE has risen to 10.2% from 7.5% a year ago, signaling enhanced shareholder value creation.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
13.3%
Latest Quarter
Free Cash Flow
$412118000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Since net income is positive ($148.8 million in Q1 2026), the trailing P/E ratio of 39.8x is the primary valuation metric. The forward P/E of 33.1x implies that earnings are expected to grow, and the gap between trailing and forward multiples suggests the market anticipates continued earnings expansion. The P/S ratio of 0.59x provides a secondary check, indicating the stock is reasonably priced relative to its revenue base. Compared to the healthcare services industry, BrightSpring trades at a premium: the trailing P/E of 39.8x is above the sector average of approximately 22x (based on industry data), representing an 81% premium. This premium is justified by the company's superior revenue growth (25.6% YoY vs. industry average of ~10%) and expanding margins, as well as its dominant position in the complex-care pharmacy niche. Historically, the stock's P/E has ranged from a low of -88.4x (when unprofitable) to a high of 118x (in early 2023). The current trailing P/E of 39.8x is near the lower end of its historical range over the past two years, suggesting that despite the stock's price appreciation, earnings growth has kept pace, and the valuation is not excessively stretched relative to its own history.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BrightSpring's debt-to-equity ratio of 1.44 is elevated, and interest expense of $38.6M in Q1 2026 consumes about 32% of operating income ($121.4M). While free cash flow of $101.4M provides coverage, rising interest rates could pressure earnings. The company's net margin, though improving to 4.1%, remains thin, leaving little room for error. Revenue concentration in the Pharmacy Solutions segment (majority of revenue) poses a risk if payer mix shifts unfavorably or if patient volumes decline. The current ratio of 1.57 indicates adequate liquidity, but the high debt load warrants monitoring.
Market & Competitive Risks: The stock's trailing P/E of 39.8x is an 81% premium to the industry average of ~22x, making it vulnerable to valuation compression if growth decelerates. With a beta of 1.795, the stock amplifies market moves, and a broad market selloff could trigger sharp declines. The wide analyst target range ($49-$90) reflects uncertainty about future growth and margin trajectories. Competitive pressures in the home and community-based healthcare space could erode market share or pricing power. Regulatory risks include potential changes to Medicare/Medicaid reimbursement rates, which directly impact revenue.
Worst-Case Scenario: In a severe downturn, the stock could retest its 52-week low of $19.01, representing a 73% decline from the current price of $70.69. This scenario could be triggered by a combination of factors: a sharp deceleration in revenue growth (e.g., below 10%), margin compression from rising costs or unfavorable payer mix, and a broad market correction. The analyst low target of $49.00 implies a 30.6% downside, but the 52-week low represents a more extreme but plausible worst case. Investors could lose up to 73% of their investment in this adverse scenario.
FAQ
The key risks are: 1) Valuation risk: Trailing P/E of 39.8x is 81% above the industry average, making the stock vulnerable to multiple compression if growth slows. 2) Financial risk: Debt-to-equity ratio of 1.44 is elevated, and interest expense of $38.6M consumes a significant portion of operating income. 3) Market risk: Beta of 1.795 means the stock is 80% more volatile than the S&P 500, amplifying losses in a downturn. 4) Regulatory risk: Revenue depends on Medicare/Medicaid reimbursement; policy changes could impact growth. The most severe risk is a growth deceleration leading to a 30-73% decline from current levels.
The 12-month forecast includes three scenarios: Bull case (30% probability) targets $75-$90, driven by sustained growth above 25% and net margins above 5%. Base case (50% probability) targets $65-$75, with growth moderating to 15-20% and margins improving gradually. Bear case (20% probability) targets $49-$60, with growth decelerating below 10% and margin contraction. The base case is most likely, assuming the company maintains its growth trajectory but at a more sustainable pace. The analyst average target of $75.22 aligns with the base case, implying modest upside from the current price of $70.69.
BTSG's trailing P/E of 39.8x is above the healthcare services industry average of ~22x, indicating a premium valuation. However, this premium is justified by the company's superior revenue growth (25.6% YoY vs. industry ~10%) and expanding margins. The forward P/E of 33.1x suggests earnings growth is expected. The P/S ratio of 0.59x is reasonable relative to revenue scale. Historically, the stock's P/E has ranged from -88.4x to 118x, and the current 39.8x is near the lower end of its recent range, suggesting it is not excessively overvalued. Overall, BTSG appears fairly valued given its growth trajectory, but it is not a bargain.
BTSG is a good buy for growth-oriented investors with a higher risk tolerance. The stock offers accelerating revenue growth (25.6% YoY), rapidly expanding margins (net margin from 0.9% to 4.1%), and strong free cash flow ($101.4M in Q1). Analyst consensus is Strong Buy with an average target of $75.22, implying 6.4% upside. However, the trailing P/E of 39.8x is an 81% premium to the industry average, and the stock's beta of 1.795 means high volatility. The biggest downside risk is a growth deceleration leading to multiple compression. For investors who believe the growth story is sustainable, it is a good buy; for those seeking stable value, it may be too risky.
BTSG is more suitable for long-term investment given its growth stage and volatility. The company is in a high-growth phase with accelerating revenue (25.6% YoY) and expanding margins, but its beta of 1.795 makes it prone to sharp short-term swings. The stock does not pay a dividend (yield 0%), so returns depend on capital appreciation. For long-term investors (3-5 years), the growth story could compound significantly if margins continue to expand. Short-term traders may find opportunities in momentum, but the wide analyst target range ($49-$90) indicates uncertainty. A minimum holding period of 12 months is recommended to allow the growth thesis to play out.